The researchers hope to find a way of genetically characterizing patients to predict responsiveness to treatment, and help physicians to determine the best treatment option for their patients.
The genetic characteristics of 200 women will be studied by comparing those who responded to a standard carboplatin/tamoxifen regimen for breast cancer with those who did not.
“The goal is to identify genetic factors that will enable physicians to predict the outcome and efficacy of carboplatin/tamoxifen treatment, a standard therapy for victims of breast cancer,” stated Dr Hector Gomez, chairman and chief medical officer of DNAPrint genomics.
This marks the second collaborative project between DNAPrint and the Genomics Collaborative Division of SeraCare Life Sciences.